Research News

OrigAMI-4 study shows strong tumor responses in patients with recurrent or metastatic head and neck cancer after standard treatments fail. Johnson & Johnson has announced promising clinical results for its investigational therapy RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) in patients with advanced head and neck squamous cell carcinoma (HNSCC), a disease where treatment options remain limited once standard therapies stop working.

Atherosclerosis, the gradual buildup of fatty deposits inside arteries, remains one of the leading causes of heart attacks and strokes worldwide. While inflammation has long been recognized as a major contributor to the disease, new research from scientists at Ludwig Maximilian University of Munich suggests that certain inflammatory immune cells may also play a protective role in slowing its progression.

Medicines commonly prescribed to treat anemia in patients with chronic kidney disease may have an unexpected role in cancer therapy, according to a new study from Finland. Researchers have found that a class of anemia drugs known as HIF-prolyl hydroxylase inhibitors (HIF-PHIs) can interfere with cancer-related processes, potentially helping patients manage both anemia and tumor progression at the same time.

Scientists at Nanyang Technological University, Singapore have developed an ultra-small surgical robot capable of performing five different medical functions wirelessly inside the body, marking a major step toward more precise and minimally invasive treatments.

Eli Lilly has announced encouraging results from its late-stage Phase 3 clinical trial of retatrutide, an investigational next-generation obesity treatment that delivered dramatic weight reduction in adults living with obesity or overweight conditions.